Barcelona, Catalonia, Spain
Lead precision medicine and companion diagnostic (CDx) activities across global oncology clinical trials, driving biomarker strategies from laboratory set-up through study close-out and regulatory submissions. Partner with cross-functional teams, including Clinical Development, Translational Medicine, Regulatory Affairs, Clinical Operations, Data Management and external diagnostic partners, to deliver precision medicine objectives. Oversee biomarker assay implementation, laboratory operations and vendor performance, ensuring high-quality execution and regulatory compliance. Identify and mitigate scientific and operational risks impacting biomarker and CDx deliverables, support global regulatory submissions through biomarker documentation and clinical development contributions, and drive continuous improvement initiatives to strengthen precision medicine processes and cross-functional collaboration.
Technical lead in the space of GU cancers and ctDNA, making sure bladder cancer patients get access to the best care. Additionally, working with the early detection team to assess technological readiness of early-detection cancer screening technologies.
Mainly, I was responsible for devising comprehensive project management strategies essential for both internal and external project development centered around circulating nucleic acids. Additionally, I played a crucial role in cultivating a robust network of connections, engaging Key Opinion Leaders (KOLs), and stakeholders, to effectively introduce Flomics' products and services to customers. Simultaneously, I undertook a secondary role within the business development department. Here, I closely monitored industry competition, formulating strategies to position Flomics' products favorably in the market. Moreover, I assumed the responsibility of safeguarding intellectual property through a combination of patents and trade secrets. Alongside this, I managed the process of securing public funding via grant applications. Furthermore, I collaborated closely with the communications and marketing team. My involvement ensured that all materials produced were rooted in scientific integrity, tailored appropriately to suit the audience's background and understanding.
As Scientific Lead, I guided the R&D line of Flomics Biotech focusing on the discovery of circulating RNA for the early detection of cancer while acting as project manager and person of contact for our internal and external projects.
Freelance consultant with expertise in bioinformatics from a wet lab perspective. Founder of "Into the dry lab", where we bring dry lab expertise to wet lab scientists to shape the future of science and make sure you can carry on your own studies, from start to end.
Involvement in the following projects: - Discovering new circulating microRNAs as biomarkers of head and neck squamous cell carcinoma. - Studying EV-plasma microRNAs to discriminate between different cancer types and healthy donors - Role of Nivolumab in the alteration of circulating microRNA profiles of patients with head and neck cancer. - EV-derived microRNA profiles from patients with classical Hodgkins Lymphoma discriminate between patients with active disease and those in remission.
-Identification of the molecules involved in the specific packaging of miR-503 into exosomes in endothelial cells under chemotherapeutic treatment. -Study of the co-export of microRNAs and their target mRNAs into exosomes. -Study of the involvement of AGO2 and GW182 in the packaging and export of microRNAS into exosomes